Spring Creek Capital’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Spring Creek Capital’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-460,200	Closed	-$4.47M	–	116
2022 Q1	$4.47M	Hold	460,200	–	–	0.18%	108
2021 Q4	$4.46M	Hold	460,200	–	–	0.17%	95
2021 Q3	$4.46M	Buy	+460,200	New	+$4.49M	0.22%	99

Other funds holding NKGN

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Spring Creek Capital's NKGN Position: Q2 2022 in Review

Spring Creek Capital sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2022, closing a stake of 460,200 shares — an estimated $4.47M sold.

Spring Creek Capital first reported a position in NKGN in Q3 2021 and held it in 3 quarters. The position peaked at $4.47M in Q1 2022. 48 funds tracked by Wall St. Rank hold NKGN as of Q2 2022.

Spring Creek Capital reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 460,200 NKGen Biotech, Inc. Common Stock shares in Q2 2022, an estimated $4.47M.
Spring Creek Capital first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
Spring Creek Capital's NKGen Biotech, Inc. Common Stock position peaked at $4.47M in Q1 2022.
48 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.